Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DISPERSE-2 dose confirmation study of AZD6140 plus aspirin versus clopidogrel plus aspirin in non-ST-segment elevation acute coronary syndromes
2004-000352-16Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2004
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute coronary syndrome (ACS) comparing AZD6140 + acetylsalicylic acid with clopidogrel + acetylsalicylic acid (2 arms). Primary endpoint: Total bleeding events excluding minimal bleeds within first 4 weeks. Started Jul 2004; status: completed.
02
Drugs
ticagrelorclopidogrelaspirin
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on 2004-000352-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000352-16.